Lineage Cell Therapeutics (LCTX) Earnings Date, Estimates & Call Transcripts → Shocking $16T Elon Musk Crypto Leak (From Crypto 101 Media) (Ad) Free LCTX Stock Alerts $1.09 +0.03 (+2.83%) (As of 05/17/2024 ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartEarningsHeadlinesInsider TradesOwnershipShort InterestStock AnalysisAnalyst ForecastsChartEarningsHeadlinesInsider TradesOwnershipShort Interest Earnings SummaryLatest Earnings DateMay. 9EstimatedActual EPS (May. 9) -$0.04 Consensus EPS (May. 9) -$0.04 Read Call TranscriptListen to Call Get Lineage Cell Therapeutics Earnings AlertsEnter your email address below to receive the latest news and earnings results for LCTX and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueLCTX Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.LCTX Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Banyan Hill PublishingCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Nvidia’s CEO calls it the “next amazing revolution” … and even declared it “is going to be flat out of the biggest [revolution] ever.” Jeff Bezos, Bill Gates, and Mark Zuckerberg have invested billions in it.Click on Adam's shiny forehead for more details. Lineage Cell Therapeutics Analyst EPS EstimatesCurrent Year EPS Consensus Estimate:($0.12) EPSNext Year EPS Consensus Estimate: ($0.12) EPSLCTX Earnings Date and InformationLineage Cell Therapeutics last announced its quarterly earnings data on May 9th, 2024. The reported ($0.04) earnings per share for the quarter, hitting the consensus estimate of ($0.04). The company had revenue of $1.44 million for the quarter, compared to analysts' expectations of $2.22 million. Lineage Cell Therapeutics has generated ($0.14) earnings per share over the last year (($0.14) diluted earnings per share). Earnings for Lineage Cell Therapeutics are expected to remain at ($0.12) per share in the coming year. Read More Lineage Cell Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript5/9/2024Q1 2024($0.04)($0.04)-($0.04)$2.22 million$1.44 million 3/7/2024Q4 2023($0.07)($0.03)+$0.04($0.03)$4.74 million$2.09 million11/9/2023Q3 2023($0.04)($0.04)-($0.04)$3.30 million$1.25 million8/10/2023Q2 2023($0.04)($0.03)+$0.01($0.03)$2.65 million$3.23 million 5/11/2023Q1 2023($0.03)($0.03)-($0.03)$3.04 million$2.39 million3/9/2023Q4 2022($0.03)($0.03)-($0.03)$2.97 million$1.92 million Get the Latest News and Ratings for LCTX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Lineage Cell Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 11/10/2022Q3 2022($0.03)($0.04)($0.01)($0.04)$4.11 million$3.00 million8/11/2022Q2 2022($0.03)($0.04)($0.01)($0.04)$4.86 million$4.55 million5/12/2022Q1 2022$0.01($0.04)($0.05)($0.04)$12.07 million$5.24 million3/10/2022Q4 2021($0.04)($0.05)($0.01)$0.07$1.20 million$1.20 million 11/10/2021Q3 2021($0.05)($0.05)-($0.05)$0.56 million$2.27 million 8/12/2021Q2 2021($0.03)($0.03)-($0.03)$1.05 million$0.51 million Lineage Cell Therapeutics Earnings - Frequently Asked Questions When did Lineage Cell Therapeutics announce their last quarterly earnings? Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) last announced its quarterly earning data on Thursday, May 9, 2024. Learn more on LCTX's earnings history. Did Lineage Cell Therapeutics beat their earnings estimates last quarter? In the previous quarter, Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) reported ($0.04) earnings per share (EPS) to hit the analysts' consensus estimate of ($0.04). Learn more on analysts' earnings estimate vs. LCTX's actual earnings. How can I listen to Lineage Cell Therapeutics's earnings conference call? The conference call for Lineage Cell Therapeutics's latest earnings report can be listened to online. Listen to Conference Call How can I read Lineage Cell Therapeutics's conference call transcript? The conference call transcript for Lineage Cell Therapeutics's latest earnings report can be read online. Read Transcript How much revenue does Lineage Cell Therapeutics generate each year? Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) has a recorded annual revenue of $8.94 million. How much profit does Lineage Cell Therapeutics generate each year? Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) has a recorded net income of -$21.49 million. LCTX has generated -$0.14 earnings per share over the last four quarters. What is Lineage Cell Therapeutics's EPS forecast for next year? Lineage Cell Therapeutics's earnings are expected to stay at ($0.12) per share in the next year. More Earnings Resources from MarketBeat Related Companies: ELEV Earnings FENC Earnings KOD Earnings IPSC Earnings ADVM Earnings INMB Earnings CGEN Earnings ABOS Earnings CMPX Earnings ZURA Earnings Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: Baidu Stock Earnings Prove Ray Dalio Right about China?Home Depot: Earnings Mixed, Wait to Buy the DipTraders Sell but Investors Still Win After Palantir's EarningsTech Earnings Insights: Where Opportunity Meets UncertaintyApple’s Earnings Show Investors Its Strength and Its WeaknessCarvana’s Q1 Earnings: A Profitability U-TurnPayPal’s Strong Earnings Growth and Strategic Evolution This page (NYSEAMERICAN:LCTX) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaA letter is coming from the "Bureau of the Fiscal Service".Stansberry ResearchHe called Apple at $1.49 and now he says: “Buy these 6 AI stocks.”InvestorPlaceCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingMake this ONE trade on Tuesday at 2 p.m. EST!Monument Traders Alliance[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lineage Cell Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.